Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium. Dickstein Y, et al. Among authors: dishon benattar y. BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956. BMJ Open. 2016. PMID: 27098822 Free PMC article. Clinical Trial.
Reply to Zavascki and Nation.
Paul M, Yahav D, Dishon Benattar Y, Leibovici L. Paul M, et al. Among authors: dishon benattar y. Clin Infect Dis. 2017 Mar 1;64(5):696. doi: 10.1093/cid/ciw819. Clin Infect Dis. 2017. PMID: 27986667 No abstract available.
The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M; AIDA Study Group. Zak-Doron Y, et al. Among authors: dishon benattar y. Clin Infect Dis. 2018 Nov 28;67(12):1815-1823. doi: 10.1093/cid/ciy371. Clin Infect Dis. 2018. PMID: 29718143 Clinical Trial.
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group. Dickstein Y, et al. Among authors: dishon benattar y. Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988. Clin Infect Dis. 2019. PMID: 30462182 Clinical Trial.
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA Study Group. Dickstein Y, et al. Among authors: dishon benattar y. Clin Infect Dis. 2020 Dec 17;71(10):2599-2607. doi: 10.1093/cid/ciz1146. Clin Infect Dis. 2020. PMID: 31758195 Clinical Trial.
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
Kristoffersson AN, Rognås V, Brill MJE, Dishon-Benattar Y, Durante-Mangoni E, Daitch V, Skiada A, Lellouche J, Nutman A, Kotsaki A, Andini R, Eliakim-Raz N, Bitterman R, Antoniadou A, Karlsson MO, Theuretzbacher U, Leibovici L, Daikos GL, Mouton JW, Carmeli Y, Paul M, Friberg LE. Kristoffersson AN, et al. Among authors: dishon benattar y. Clin Microbiol Infect. 2020 Dec;26(12):1644-1650. doi: 10.1016/j.cmi.2020.03.016. Epub 2020 Mar 22. Clin Microbiol Infect. 2020. PMID: 32213316 Free article. Clinical Trial.
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Among authors: dishon benattar y. Clin Microbiol Infect. 2020 Sep;26(9):1185-1191. doi: 10.1016/j.cmi.2020.03.035. Epub 2020 Apr 3. Clin Microbiol Infect. 2020. PMID: 32251844 Free article. Clinical Trial.
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance.
Frenk S, Temkin E, Lurie-Weinberger MN, Keren-Paz A, Rov R, Rakovitsky N, Wullfhart L, Nutman A, Daikos GL, Skiada A, Durante-Mangoni E, Dishon Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Geffen Y, Gershon R, Paul M, Carmeli Y. Frenk S, et al. Among authors: dishon benattar y. J Antimicrob Chemother. 2022 Mar 31;77(4):934-943. doi: 10.1093/jac/dkac010. J Antimicrob Chemother. 2022. PMID: 35084023
Duration of antibiotic treatment for Gram-negative bacteremia - Systematic review and individual participant data (IPD) meta-analysis.
Turjeman A, von Dach E, Molina J, Franceschini E, Koppel F, Yelin D, Dishon-Benattar Y, Mussini C, Rodríguez-Baño J, Cisneros JM, Huttner A, Paul M, Leibovici L, Yahav D. Turjeman A, et al. Among authors: dishon benattar y. EClinicalMedicine. 2022 Dec 1;55:101750. doi: 10.1016/j.eclinm.2022.101750. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36483269 Free PMC article.
15 results